Company Filing History:
Years Active: 2013-2014
Title: Mi Zhang: Innovator in Bacterial Cell Control
Introduction
Mi Zhang is a prominent inventor based in Toronto, Canada. He has made significant contributions to the field of bioengineering, particularly in the treatment of bacterial infections. With a total of 2 patents, his work focuses on innovative methods to control bacterial cells and persister cells using electrochemical processes.
Latest Patents
Mi Zhang's latest patents include a "System and method for controlling bacterial cells with weak electric currents." This invention outlines a system that utilizes weak electric currents to effectively eliminate bacterial cells. The method can be adapted for novel therapies targeting chronic infections and controlling persistent biofouling. It has broad applications in treating chronic and drug-resistant infections, including those caused by methicillin-resistant bacteria.
Another significant patent is the "System and method for controlling bacterial persister cells with weak electric currents." This invention also employs an electrochemical process to treat persister cells, enhancing efficacy through synergistic effects with antibiotics. Similar to his previous patent, this method is designed for chronic infections and has potential applications in decontaminating medical devices.
Career Highlights
Mi Zhang is affiliated with Syracuse University, where he continues to advance research in bioengineering and infection control. His innovative approaches have garnered attention in the scientific community, contributing to the development of new therapeutic strategies.
Collaborations
Mi Zhang collaborates with notable colleagues, including Dacheng Ren and Tagbo Niepa. Their combined expertise enhances the research and development of effective treatments for bacterial infections.
Conclusion
Mi Zhang's work represents a significant advancement in the fight against bacterial infections. His innovative patents and research at Syracuse University highlight the potential for new therapies that can address chronic and drug-resistant infections.